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Summary.-The parametric statistical models discussed include all those which
have previously been described in the literature (Boag, 1948-lognormal; Berkson
and Gage, 1952-negative exponential; Haybittle, 1959-extrapolated actuarial) and
the basic data used to test the models comprised some 3000 case histories of patients
treated between 1945 and 1962. The histories were followed up during the period
1969-71 and thus provided adequate information to validate long-term survival
fractions predicted using short-term follow-up data. The results with the log-
normal model showed that for series of staged carcinoma cervix patients treated
during a 5-year period, satisfactory estimates of long-term survival fractions could
be predicted after a minimum waiting period of 3 years for stages I and II, and 2
years for stage III. The model should be used with a value assumed for the log-
normal paramater S in the range S = 0-35 to S = 0 40. Although alternative models
often gave adequate predictions, the lognormal proved to be the most consistent
model. This model may therefore now be used with more confidence for prospective
studies on carcinoma cervix series and can provide good estimates of long-term
survival fractions several years earlier than would otherwise be possible.
ALTHOUGH the 5-year survival rate or, for us and if the logical framework of a
in more general terms, the m-year survival model can be shown to be valid, the
rate, determined from an m-year follow-up evaluation of the various parameters is
of all the surviving patients, is widely now easy. Such models do provide a
used as a criterion of success in cancer way of bringing to bear a great deal of
therapy, it is too crude and too long valuable past experience upon the assess-
delayed a statistic to be a satisfactory ment of new short-term results. Indeed,
way of comparing alternative treatments they often allow a useful prediction of
during the working life of a surgeon or longer term results to be made from the
radiotherapist. Even if this rate is as- available short-term data. Moreover, the
sessed by the actuarial (i.e. life table) detailed classification they demand can
method, it still requires that a consider- be ofhelp in assessing whether an improve-
able proportion of all cases shall have ment in m-year survival rate is due to
survived the full m-year term. Statistical long-term cures or merely to protracted
models which attempt to allow for the survival with cancer. Confidence in any
delayed mortality during the follow-up such model must, however, be built up
period have rarely been used, partly by its successful use on actual follow-up
perhaps because when they were first data. This can be done retrospectively
put forward (Boag, 1949; Berkson and by using records of cases treated many
Gage, 1952) the tedious computation in- years ago and followed up at intervals
volved had to be done by hand. The until death with or without cancer or
digital computer has solved that problem long-term symptom-free survival had been
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proved. However, detailed case histories several possible statistical models which
are necessary and these are not readily have been suggested, and some new
available in sufficient numbers or over ones.
long enough periods certainly not in a These tests have been made in 2
single cancer centre. The Regional Can- stages-firstly, the actual survival time
cer Registries which provide data for distribution for each group of patients
the Office of Population Censuses and examined has been compared, for each
Surveys do, indeed, have data in model, with the postulated analytical
bulk but not in sufficient detail for form, choosing the model parameters to
testing a parametric model, and since give the best fit, and assessing the good-
1970 they are no longer required to ness of fit achieved by a x2 test. Second-
record the disease stage (O.P.C.S., 1970). ly, accepting only the limited survival
Also, there is no uniformity of data data which would have been available
collection, storage and retrieval within a few years (2, 3 or 4 years) after the end
the medical records departments of dif- of the 5-year period under review, the
ferent hospitals. The only accurate models were used to predict the 7-year,
method of obtaining the essential treat- 10-year or 15-year survival fractions as
ment and follow-up information is to well as the proportion of long-term
consult the original hospital case records cures " C ". These predicted values were
at a number of centres. then compared with the observed 7-, 10-,
For the present study on a single or 15-year results, taking account of the
site carcinoma cervix uteri-material standard errors of both predicted and
has had to be gathered from 6 large observed results. The rationale of this
cancer centres, covering a 25-year period. " prediction " and "proof" test is illus-
We have used this material to test trated in Fig. 1.
Time Scale. Years.
Year when initial
patient treated
Year when final Yawh follow-ip
patient treated details were
y ediction transcribed from the Y patient case notes
P (Yf+ n) (T+ m) Y
Treatment 1969 1971
Interval
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MATERIALS AND METHODS TABLE II.-Grouping by Stage, Hospital
Patients and Treatment Period
Two major factors which affect prognosis Treatment Total Reference
in cancer are the site of the disease and the Hospital period Stage cases letter
stage it has reached before treatment. For CHUM 1945-49 I 138 A
this study we have therefore selected a CHUM 1950-54 I 179 B
single site and have separated cases into z 1945-49 I 101 D
stage groups before analysis. Between 1969 z 1950-54 I 127 E
and 1972 some 6000 case histories were Z 1955-59 I 292 F
examined of women treated between 1925 N 1955-59 I 553 G
and 1962at the hospitals listed inCHUM 1945-59 I 582 AA and 1962 at the hospitals listed in Table 1. z 1945-59 I 520 BB
TABLE I.-Carcinoma Cervix Case His- H 1945-49 II 68 H
C 1945-49 II 110 I tories Availablefor Analysis mu 1945-49 II 97 J
MU 1950-54 II 86 K
Treatment C 1950-54 II 144 L
Stage Hospital years H 1950-54 II 143 M
I-IV Middlesex 1925-62 C 1955-59 II 117 N
I-IV Royal Marsden and Chelsea 1929-62 MU 1955-59 II 123 0
I-IV University College 1941-62 H 1955-59 II 152 P
I-IV Hammersmith 1942-62 CHUM 1045-59 II 1040 CC
I Christie, Manchester 1945-59
I Oslo 1955-59 CHUIM 1945-49 III 170 Q
CMU 1950-54 III 115 R
H 1950-54 III 90 S
For those London hospitals included, all mu 1955-59 III 77 T
case records still available were reviewed H 1955-59 III 78 U C 1955-59 III 78 v and these data are therefore complete in CHUM 1945-59 III 608 DD
the sense that no further data exist at these
hospitals for carcinoma cervix treatments CHUM 1945-59 I+II+III 2230 EE
before 1962. It can be assumed that data
before 1945 are fragmentary inasmuch as
many of the early records have either been The stage IV group was also small and
lost or destroyed. In view of this uncer- wasgatheredonlyfromtheLondonhospitals
tainty, only post-1945 records have been Stage IV is not of any value for testing used to test the various statistical models predictive models but we have tested its
and the post-1945 era has been subdivided conformity with the survival time distribu-
into three 5-year treatment periods-1945- tion of the unsuccessfully treated cases.
49, 1950-54 and 1955-59. Since the records The letters C, H, U, M, Z and N refer to the
were examined in the period 1969-72 there 6 hospital centres of Table I.
was a minimum follow-up period of 20 years
for the 1945-49 group, of 15 years for the
1960-54 group and of 10 years for the Methods
1955-59 group. (a) Construction of a statistical model.-
The stage I groups from the 4 London When a large group of patients is treated for
hospitals were much smaller than the stage II cancer, a temporary remission is achieved in
or stage III groups, and therefore additional many cases and in some there is no return of
data for stage I was obtained from Man- the disease before the death of the patient
chester and from Oslo for the period 1945-59. from some other cause many years later.
Table II shows the grouping of cases avail- Although one cannot claim a certain " cure "
able to test the validity of the different in any individual case, in view ofthe residual
statistical models. For stages I-Ill there risk of recurrence, it is surely not unduly
are data from at least 2 different single or optimistic to attempt to distinguish and
grouped centres for each 5-year treatment estimate a " proportion cured " by appro-
period, except for stage III during the priate statistical techniques applied to any
period 1945-49 where only a single group large group of patients. Two kinds of
from the London hospitals was available. model have been proposed and we shall532 R. F. MOULD AND J. W. BOAG
TOTAL CASES
TREATED
r
PROPORTION CURED PROPORTION NOT CURED
N (t)
Death rate
of cases
who die
with Ca.
, / ~~~~~~~~Cervix .
present. Tail
olArea/
t SURVIVAL TIME (t)
T
N (t). dt = 1 and Q =j N (t). dt
FIG. 2. Statistical modlel, Type I.
test both kinds against the data on cervix _ log t- M
cancer listed in earlier paragraphs. where x -
The first kind of model explicitly recog-
nizes the existence of a proportion cured, N(t) =x . exp (-axt) (2)
denoted by C, and assumes that only the
complementary fraction (1/C) is at risk for IN(t) y t exp Y. ,It) (3)
a recurrence of cancer although, of course, 12
all are at risk for other causes of death
(Fig. 2). To complete a model of this N(t) No . t exp (-y . tc) (4)
kind, it is necessary to find an appropriate
formula for the distribution of survival times~~~~ ~ whc ocu wihi thsfato Table III lists the sources of these
several proposals and the methods of analysis (1/C). The general shape of the curve is used.
skew, the mortality from persistent or The second type of model (Fig. 3), was
recurrent cancer reaching a peak during the first put forward by Haybittle (1959) and
first one or 2 years after treatment and
declining gradually thereafter. Several ana- was called by him the "extrapolated
lytical forms for this curve have been pro- carial" mode postulateslan anayi
pose,amng tem he lgnoral crvecal form for the gradually declining cancer posed, among them the lognormal curve mortality which affects the whole group of (equation 1), the negative exponential (equa- patients subsequent to treatment. Although
tion 2) and the skew exponential (equation the " cured " group was not explicitly
3). The latter is a particular example of postulated, it is implicit in this model also,
a family of skew curves with the general since
equation 4. who~~~~lne the declining mortality causes the equation*4. whole group of patients to approach asymp-
N(x) - exp (-1 X2) (1) totically a fixed fraction of its original size,
/27r 2 which then survives from cancer indefinitely.ESTIMATING SUCCESS RATE IN TREATMENT OF CARCINOMA CERVIX UTERI 533
TABLE III.-Parameters of the Various Models
Method of
Model determination
type Model Reference Parameters of parameters
I Lognormal Boag (1949) M (logtime) Maximum likelihood
S
C
Negative exponential Berkson and Gage (1952), cx (time)-' Least squares or
.HIaybittle (1959) C maximum likelihood
Skew exponential Mould (1973) y (time)-'/2 Maximum likelihood
C
II Extrapolated actuarial Haybittle (1959) ,B (time)-' Maximum likelihood
K for K and8
C C = exp (-K/fl)
Haybittle (1965) ft (time)-' Maximum likelihood
C
Skewed extrapolated actuarial The current paper E (time)-' Maximum likelihood
C
Total Cases Treated where N is the number surviving to time t
and 0(t) is any function satisfying the
conditions En~~~~~~~~~~~~~00+(t) dt = 1 and +(t) -O0
as t -x oc then we can deduce that
MORTALITY CURVEN N g * , /4t) dt
JN, [oC] 0
that is
Death % log log .D 4)(t)
Rate of
all cases 8 \ ss where D is the integral of b. Therefore as
in the series E t-> oo -* andso
N_
N0 _> C
Survival Time, t. and C measures the ultimate cure rate.
Thus we may write
SURVIVAL CURVE NN
- (C)+@(t)
1 where
SurvivalI 4)(t)=| 0(t)dt.
Fraction o
when causes The function b can therefore be chosen
of death other with considerable freedom to provide a
than ca.cervix _ _ _.good fit to the observed or expected dis-
are ignored c tribution ofsurvival times. Ca deaths in any
interval are then
Survival Time, t. N1- N2 = N0{(C)+D(ti) -(C)+O(t,)
or, we may express the same relationship
FIG. 3.-Statistical model, Type II. by saying that the probability that an
individual patient in the treated group
If we put shall die of cancer in the interval (tl, t2) is
- dN =N . log (1V0(t) dt (N1- N2)/No, i.e. is
acJ {(C)+(D(ti) -(C) (W534 R. F. MOULD AND J. W. BOAG
Patient follow-up group CODE:
1 = Died, ca. cervix present.
2 = Died, intercurrent disease.
3 = Alive with no sign of recurrence.
4 = Alive with ca. cervix present.
5 = Died, no data on cause of death.
6 = Died, intercurrent disease, but
no available data about ca. cervix
9 Died indirectly due to treatment.
10
- Died, second primary cancer unrelated
to ca. cervix was present.
Appar Disease Survival Time Terminal Disease
4 = Free Time D w lt n be
Initial Planned Treatment (0 reZ d alive neore quaterof th. CODE: R
- Radiotherapy only, ; eoddt h ers ure-ot) _
S
- Surgery only, R + S = Radiotherapy
and Surgery. , -Age
Histology CODE: 1
- Squamous cell, 1 29.
2=FeCarcinoma, no further detailss f t [liltcard system.
3 = Biopsey negative, no recorded b tied r ( Data 8toraq andmri th sur-
histology, 4 = Adenocarcinoma, i(u wihe dgtal
5sTransitional cell, 7 = Any other e c t t
histology not covered by codes 1 - 5 Hospital Treatment Annual dates for le
CODEl Site. Start of initial planned
2a=C CODE treatment, estimated date
3 = U 14
a Cervix of recurrence (if any),
4 = H Date when last known to be
6 a Z alive - or - Date of death.
7
- N CODE: 1 = 1931, 2
- 1932 ..
8 s M ~~~. . .. 12 =1942, .....32 1962. . .
FIG. 4.t Parameter codes for the punched card system.
Various expressions have been tried for (b) Data storate andretrievaa . This sur-
the function +(t). Haybittle (1959, 1965) vey was undertaken at a time when digital
chose 0(t) =b . exp (-agt) and called this computers were readily available for cal-
the " extrapolated actuarial " model. We culation but much less available for data
shall test this model in various ways in later storage and retrieval for these functions
paragraphs using our carcinoma cervix data. make quite different demands onthe machine.
This form for 0(t) implies that cancer mor- The number of cases we had to examine was
tality in the treated group will be a raximum not too largeq some 6000 to be dealt with
att = 0,thatis,immediatelyaftertreatment, manually on an edge-punched card system
whereas all clinical experience indicates that and we chose thisfor our database, extracting
mortality is low at t-0 and rises to a peak all the relevant information for each patient
which occurs at anything from a few months onto a single 8 X 5 inch card of the design
to a few years after treatment, depending illustratedin Fig. 4 which shows the Formica
on the site and stage of the disease. The template used to assist punching the data.
various skew curves tried out in the Type I All the information for each patient was thus
models to fit the distribution of survival in an immediately visible form, making
times may be tested again as hypotheses checking easy, and the cards could be sorted
for +(t). In an attempt to find a simple quickly into their variousgroupings by means
single parameter representation for 0(t), of the edge-punched holes and slots. Sur-
wehavetestedtheform0(t) = E2texp(-,Et), vival time data derived from these card
calling, this the skewed extrapolated actu- sorting operations were punched onto paper
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puter in this form for the necessary statistical other models uses only 2. This extra
estimation procedures. parameter makes the distribution curve more
(c) Estimation of the parameters of the flexible and thus facilitates a good fit with
statistical models being studied.-In the first the observations, but another consequence
type of test referred to in the introduction, is that the standard errors of the para-
namely, testing the " goodness of fit " of a meter values increase so that the estimate
completed histogram of survival times with of any one parameter-such as C -is less
some postulated analytical distribution, the stable. A 2-parameter model is clearly
best values of a single parameter of the simpler than a 3-parameter one and it is
distribution could be estimated directly by a shown below that the parameter S in the
standard " least squares " method. lognormal can often be treated as a constant,
When 2 or 3 parameters have to be esti- thus converting this model also to a 2-
mated simultaneously from the incomplete parameter one. In the present survey of
data of a treatment series-incomplete be- ca. cervix uteri, S = 0 40 fits practically all
cause further deaths with cancer will still be our data.
added to the histogram of survival times- (d) Extrapolated survival fractions.-The
more general estimation methods must be various models may be used simply as a
adopted and we have chosen the " method of framework for extrapolation instead of
maximum likelihood " (Lea, 1945; Fisher, attaching absolute significance to the quan-
1922). tity, C, as " proportion cured ". Thus the
The logic of this method is to take as " m-year survival fraction " may be cal-
"best " values of the parameters those culated from the model (Fig. 2) as:
which would yield the highest chance of S.F.(m) = C + (1 - C)Q(m) obtaining a sample of the type actually
observed, when the calculation ofprobability even when the parameter estimates are
is based on the chosen statistical model. based on survival data for less than m
The detailed algebra involved in applying years. This is the " prediction " indicated
maximum likelihood to the several models in in Fig. 1. The " proof" is then the actual
Table III has been given elsewhere (Mould survival fraction observed after m years
1973). The iterative computations involved follow-up when causes of death other than
in solving the equations have been carried cancer are excluded, this fraction being
out by writing programmes either in BASIC evaluated by the actuarial method as de-
or in FORTRAN IV for each ofthe models. scribed by Greenwood (1926), Merrell and
Four mutually exclusive follow-up groups Shulman (1955) and Cutler and Ederer
can be seen in the top right-hand area of (1958).
Fig. 4 with codes numbered 1, 2, 3 and 4
respectively. Groups 5 and 6 occur when RESULTS
follow-up data in the patients' notes are (a) Testing the analytical form of the
incomplete: further supplementary informa- survival time distribution
tion, if eventually available, may require
the transfer of a patient from these groups Agreement between the observed sur-
to one of the Groups 1, 2, 3 or 4. If no vival time distributions and the proposed
additional information is forthcoming, a analytical formulae was tested by group-
decision on this transfer must be taken on ing survival times into equal logarithmic
the basis ofthe last detailed follow-up report. intervals* and comparing observed with
The small Group 9 may be combined with theoretical numbers in each interval by
Group 1 and the even smaller Group 10 means of a X-squared test for the 27 combined with Group 2, of which it is a . . iT special case. Thus we can allocate all the hospital series in Table II. The theor-
cases to one or other of the first 4 mutually etical parameters were varied stepwise
exclusive follow-up groups. in the programme until a minimum x-
The lognormal model employs 3 inde- squared value was found andthe computer
pendent parameters, whereas each of the then printed out this value together
* Basically the groups were 0-6, 6-9, 9-13-5, 13-5-20-25, 20-25-30-5, 30 5-45 5, 45-5-68-5, 68-5-
102-5, 102-5-153-5, etc. but for small sample series these groups were sometimes combined in pairs.536 R. F. MOULD AND J. W. BOAG
TABLE IV.-Goodness ofFit of Data to the Skew Exponentials
P levels for different values of C
Notation: @ signifies P>0 05
-signifies P<0 05
No. of cancer Reference letter ,A__ _ _
Stage deaths (see Table II) ?=1 00 C=0-67 C=0-50 C=0-40 1=0-33 C=0-29 C=0-25
I 55 A - - - - -
I 61 B S-
I 86 C - -
I 38 D - - - -
I 37 E -
I 94 F (D (- -
I 157 G - - 0 - - - -
1 202 AA - - 0 0 03 -
1 169 BB 0 0 -
I No. of series for which a good fit 4 6 8 5 5 5 2
to the data is obtained, P>0*05
II 36 H - - 0 ) (0 0 -
II 63 I - - (- 03 03 0D
II 62 J - - D 0 (0 0
II 50 K - 0 0 0 0 ( 0
II 85 L - 0 03 0 0 0
II 78 M - (0 ( 0 3 -
II 65 N 0 0 - - - - -
II 72 0 0 0 0 0 - - -
II 79 P 00
II 590 CC - - - - - - -
II No. of series for which a good fit 3 6 7 8 7 7 4
to the data is obtained, P>0*05
III 133 Q - - - - - - -
III 96 R - - - 0 0 03
III 65 S - 0 ( (D (D -
III 54 T 0 0 0 - - - -
III 59 U - 0 0 0 - - -
III 66 V - 0 0 0 03
III 473 DD - - - - - - -
III No. of series for which a good fit 1 4 4 4 3 3 2
to the data is obtained, P>0*05
I+II+III 1265 EE - - - - - - -
In each case the symbol ((D or -) in the Table gives the result for a minimum chi-squared goodness
of fit test, for the data on that horizontal level and the skew exponential dlistribution at the head of the
vertical column.
with the corresponding values of the are tested against the data from the 4
parameters-M and S for the lognormal, London hospitals, Manchester and Oslo,
,8 for the negative exponential and y for the results are those shown in Table IV.
each member of the family of skew The data in this table are for patients
curves given by equation 4. We tried treated in the 5-year periods 1945-49,
7 members of this family with C defined 1950-54, 1955-59 and followed up until
by the formula: 1969 so that the minimum follow-up
2/(I - r) period was 10 years, which gives some assurance that the tail of the distribution
where r is integral and 1 : r 7. This of recurrences is adequately represented.
restriction ensured that integration of The C value which fits the largest propor-
equation 4 would lead to a complete tion of the individual stage groups is
gamma function and would therefore be C = 0 5. C- 067 and ( = 0 40 also pro-
easily evaluated. vide reasonable fits but curves C 1
When the skew exponential curves and -= 0-25 provide poor fits to theESTIMATING SUCCESS RATE IN TREATMENT OF CARCINOMA CERVIX UTERI 537
STAGE I STAGE II
C 8 A 6 6 -6
75 - ° 3
,o __ __._____________ .5 X
>U Y
N=138
- .- -- .3
3 J
75
= f c= it se
-I ~ ~~ ~ ~~~~~~evx cacnoa
.)6 N 7 I.3
L.~~~~~~~~~~~~~~~~~~~1
-.2
VI I6I I3
S= -25 30O*35 40 45 5O S=*.25 30O.35 40O.45 5O
Value assumed for S Value assumed for S
using the Lognormal Model using the Lognormal Model
N=Total cases in series
Minimum follow -up period = * 4 years,X 3 years,A?2years.
FiG. 5.-Comparison of observed and predicted 10-year survival fractions for stage I and stage II
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data. We have therefore concluded from complete London hospital series for 1945-
Table IV that for carcinoma cervix, 59 are combined, the data are not fitted by
C-0 5 is the best choice of exponent any skew exponential curve, nor indeed
for the skew exponential model of the by any lognormal or negative exponential
survival time distribution in follow-up curve either. For other sites also, if the
Group 1 (see Fig. 4). We have noticed data comprise a mixture of different
that if a skew exponential distribution stages, it is not usually possible to
is chosen, many published observational obtain a good fit to any of these dis-
data including sites other than the cervix, tributions.
are also best fitted by putting C 0 5 In Table V the lognormal and negative
(Boag, 1948, 1949; Wood and Boag, exponential curves are fitted to the same
1950; Smithers et al., 1952; Haybittle, observational data, again using minimum
1959; Ronnike, 1968; Sorensen, 1958). x2 to fix the best values ofthe parameters.
It is noticeable that when all the It is seen that the 2-parameter lognormal
TABLE V.-Goodness ofFit ofData to the Lognormal andSimple Exponential Distributions
P levels for different distributions
Notation: ® signifies P>005
- signifies P<005
No. of cancer Reference letter Negative
Stage deaths (see Table II) Lognormal exponential
I 55 A -
I 61 B
I 86 C 3
I 38 D -
I :37 E
I 94 F
I 157 G
I 202 AA
I 169 BB 3-
I No. of series for which a good fit 8 5
to the data is obtained, P>0* 05
II 36 H
II 63 I
II 62 J (D
II 50 K
II 85 L 3
II 78 M
II 65 N
II 72 0
II 79 P
II 590 CC
II No. of series for which a good fit 10 8
to the data is obtained, P>0* 05
III 133 Q
III 96 R
III 65 S
III 54 T
III 59 U
III 66 V
III 473 DD
III No. of series for which a good fit 7 2
to the data is obtained, P>0 05
I+II+III 1265 EE - -
In each case the symbol (03 or -) in the Table gives the result for a minimum chi-squared goodness
of fit test, for the data on that horizontal level and the distribution (lognormal or simple exponential) at
the head of the vertical column.ESTIMATING SUCCESS RATE IN TREATMENT OF CARCINOMA CERVIX UTERI 539
TABLE VI.-Summrary of the Resultsfor the Minimum Chi-squared Goodness ofFit Tests
No. of series for which a good fit to the data is obtained, P> 0*05, Total
for different distributions number
of series
The general tested
lognormal Skew exponentials for a
with M and Negative , given
Stage S variable exp. ?=1O00 C=0-67 C=0 50 C=040 C=0 33 C=0-29 C=0-25 stage
I 8 5 4 6 8 5 5 5 2 9
II 10 8 3 6 7 8 7 7 4 10
III 7 2 1 4 4 4 3 3 2 7
1+11+III 0 0 0 0 0 0 0 0 0 1
Totals 25 15 8 16 19 17 15 15 8 27
In each case the figure in the Table gives the number of series for which a good fit to the data was
obtained, P> 0 05, for the stage on that horizontal level and the distribution at the head of the vertical
column.
curve provides a good fit to all but one dictions for long-term survival fractions
of the 26 samples of data grouped indi- for many carcinoma cervix series.
vidually by stage while the negative
exponential fits only 15 of them satis-
factorily, Table VI. (b) Estimation of the long-termp survivors
When the lognormal is reduced to when a 10-year mnimumfollow-up interval
a single variable curve by fixing S equal is available
to 0 40, it still provides an adequate fit With follow-up data available in
for 20 of the 27 series of data. When 1969-71 the observation periods ranged
S is fixed and equal to 0*35, the lognormal from 10 years to 25 years and the actuarial
fits 12 series and when S is fixed and method of calculating long-term survival
equal to 0 45, it fits 24 series. Moreover, should, and does, converge towards an
when the model is used for prediction, estimate of " cure rate ". We have taken
as we shall see later, the predicted the value at 20 years subsequent to treat-
value changes little in the range S equals ment as this asymptotic value, with
0 30-0A40. which the estimates of "cure rate"
In testing the distribution of survival based on each of the parametric models
times given by " extrapolated actuarial " can be compared.
and similar models, one has to determine In addition to this comparison of
first the best values of the 2 parameters "cure rates " our computer programme
by fitting the model to the whole of the calculated for each of the 22 groups of
data and then, using these parameter cases in Table II, the expected survival
values, to calculate the expected number fractions at times 5, 6, 7, 8, 9, 10 and
of cancer deaths in each interval along 15 years after treatment using both the
the time scale for comparison with the actuarial method and each of the 5 para-
numbers observed. This we have done metric models of Table III. A detailed
for the original Haybittle model and for listing of all these results (except the
our modification of it but the results skewed extrapolated actuarial) is given by
of a X2 test showed that the original Mould (1973).
Haybittle model provided an adequate Table VII compares "cure rate"
fit for only 12/27 series and the skewed estimatesforstagesI, II and III carcinoma
extrapolated actuarial model an adequate cervix based on each model with that
fit for only 9/27 series. Nevertheless, as from the actuarial calculation. The value
will be seen later, both these type II of one standard error of the actuarial
models (Table III) give adequate pre- estimate is included in Table VII and it540 R. F. MOULD AND J. W. BOAG
TABLE VIL-Estimates of the Fraction Cured " C ", Based on the Available Long-term
Follow-up Information
20-year
survival Estimate of the fraction cured, " C ", using different models
fraction ,____
Total Reference calculated by Lognormal with an Skew Extra- Skewed
cases letter the actuarial assumed value for S exp. Nega- polated extra-
in (see method A, with tive actu- polated
Stage series Table II) (±1 s.e.) S=0-30 S=0-35 S=0-40 C=0-5 exp. arial actuarial
I 138 A 0-55 (0-05) 0-57 0-57 0-56 0-57 0.55 0-54 0-57
I 179 B 0-63 (0-04) 0-62 0-61 0-60 0-59 0-60 0-58 0-62
I 265 C 0-63 (0-04) 0-66 0-66 0-65 0-67 0-64 0-63 0-65
I 101 D 0-62 (0 05) 0-62 0-61 0-60 0-61 0-61 0-62 0-61
I 127 E 0-69 (0-04) 0-69 0-68 0-67 0-67 0-67 0-67 0-68
I 292 F 0-66 (0-03) 0-66 0-65 0-63 0-63 0-63 0-63 0-65
I 553 G 0-68 (0-03) 0-71 0-71 0-70 0-71 0-69 0-69 0-71
II 68 H 0-42 (0- 07) 0-43 0-43 0-42 0-43 0-41 0-40 0-41
II 110 I 0 37 (0-05) 0-40 0-40 0-39 0-39 0-38 0-36 0-37
II 97 J 0 33 (0-05) 0-36 0-36 0-35 0-35 0-35 0-33 0-33
II 86 K 0-37 (0- 06) 0-37 0-36 0-34 0-36 0-37 0-35 0-36
II 144 L 0-38 (0-04) 0-39 0-38 0-37 0-38 0-37 0-36 0-38
II 143 M 0-34 (0-06) 0-43 0-43 0-42 0-42 0-42 0-40 0-41
II 117 N 0-41 (0-06) 0-44 0-43 0-42 0-43 0-43 0-42 0-43
II 123 0 0-38 (0-05) 0-44 0-43 0-41 0-41 0-39 0-37 0-42
II 152 P 0-43 (0- 04) 0-44 0-43 0-41 0-41 0-40 0-38 0-43
III 170 Q 0-18 (0-03) 0-20 0-20 0-20 0-20 0-20 0-21 0-17
III 115 R 0-13 (0- 03) 0-14 0-14 0-14 0-14 0-14 0-13 0-12
III 90 S 0-25 (0- 05) 0-25 0-24 0-24 0-24 0-25 0-24 0-21
III 77 T 0-28 (0-05) 0-27 0-27 0-27 0-27 0-29 0-29 0-27
III 78 U 0-22 (0- 05) 0-20 0-20 0-19 0-20 0-22 0-22 0-19
III 78 V 0-13 (0- 04) 0-14 0-14 0-14 0-14 0-14 0-13 0-13
In each case the figure in the table for the different models gives the estimate for "C " for the data
series on that horizontal level and for the model at the head of the vertical column.
Value of Series for which patients have been
" n " followed up for at least "n " years
20 years A, D, H, I, J, Q
15 years B, E, K, L,M, R, S
10 years C, F, G, N, O, P, T, U, V
can be seenthatthe " cure rate " estimates of some 100-150 cases. The subdivision
derived by the other methods nearly all of the data into stage groups is highly
lie within one standard error of this desirable in any carefully planned clinical
actuarial estimate. Thus, with long- trial and 5 years is a reasonable period
term follow-up available it is clear that for a trial ifclinical interest and continuity
all these statistical models will give an of plan are to be maintained. Any
acceptable estimate of C. The 3 para- suggested modifications in treatment tech-
meter lognormal model requires for sta- nique can then be applied without too
bility a larger number of cases than are long a delay. Standard errors of this
available in these separate quinquennial magnitude must therefore be regarded as
groups, but the 2-parameter lognormal typical in most stratified clinical trials.
is satisfactory for any fixed value of S To reduce the error by a factor of /2
between 0-25 and 0-50 (only values for would involve doubling the sample size
0-3-0-4 are quoted in Tables). The and in this survey we have reviewed
standard errors in " C " were usually some 2000 case histories of carcinoma
close to 0-05 for the values of C en- cervix from the 4 London centres alone.
countered and the small sample sizes Clinical trials in cancer therapy are veryESTIMATING SUCCESS RATE IN TREATMENT OF CARCINOMA CERVIX UTERI 541
TABLE VIII.-Estimates ofStage I andStage II 10-yearSurvivalFractions andStage III
7-year Survival Fractions, Based on the Available Long-term Follow-up Information
10-year Estimate of the 10-year survival fraction,
survival using different models
fraction A-
Total Reference calculated by Lognormal with an Skew Extra- Skewed
cases letter the actuarial assumed value for S exp. Nega- polated extra-
in (see method -- with tive actu- polated
Stage series Table II) (±1 s.e.) S=0 30 S=0 35 S=0 40 4=0 5 exp. arial actuarial
I 138 A 0-63 (0 04) 0-58 0 59 0-60 0-64 0-61 0-61 0-61
I 179 B 0-67 (0 04) 0-65 0-66 0-66 0-67 0-69 0-69 0-66
I 265 C 0-69 (0 03) 0-67 0-67 0-67 0-67 0-68 0-68 0-66
I 101 D 0-62 (0 05) 0-63 0-63 0-64 0-63 0-64 0-65 0-62
I 127 E 0-72 (0 04) 0 70 0-71 0-71 0-72 0 73 0 73 0- 71
I 292 F 0-68 (0 03) 0-68 0-67 0-68 0-68 0-69 0-69 0-67
I 553 G 0 74 (0 02) 0-72 0-72 0-72 0-72 0 73 0 73 0-72
II 68 H 0 47 (0 06) 0 44 0 43 0 43 0 43 0 43 0 43 0-41
II 110 I 0 44 (0 05) 0-41 0-41 0-42 0-42 0 43 0-43 0-40
II 97 J 0 40 (0 05) 0 37 0 37 0-38 0-38 0 40 0 40 0-36
II 86 K 0 43 (0 06) 0-38 0 39 0 39 0 40 0 43 0 43 0-39
II 144 L 0- 41 (0- 04) 0- 39 0 39 0 40 0 40 0 40 0- 41 0- 38
II 143 M 0-46 (0 04) 0 44 0 44 0 45 0 45 0 45 0-46 0 43
II 117 N 0 45 (0 05) 0 44 0 44 0 44 0 44 0 44 0 44 0 43
II 123 0 0-42 (0.05) 0 45 0 44 0 44 0 44 0-41 0-42 0 43
II 152 P 0 43 (0-04) 0-45 0-44 0-44 0.44 0 44 0 45 0 43
7-year survival Estimate of the 7-year survival fraction,
fraction using different models
III 170 Q 0-24 (0 03) 0-20 0-21 0-22 0-22 0-22 0-23 0- 18
III 115 R 0-18 (0 04) 0-15 0-15 0-16 0-16 0-17 0-18 0-13
III 90 S 0 30 (0 05) 0-25 0-26 0-27 0-27 0-28 0-28 0-23
III 77 T 0-28 (0 05) 0-28 0-28 0-28 0-28 0-26 0 30 0-27
III 78 U 0-22 (0 05) 0-21 0-21 0-21 0-21 0-23 0-24 0-20
III 78 V 0-16 (0 04) 0-15 0-15 0-15 0-15 0-15 0-16 0-13
In each case the figure in the table for the different models gives the estimate of the 10-year (or 7-year)
survival fraction for the data series on that horizontal level and for the model at the head of the vertical
column.
Value of Series for which patients have been
" n" followed up for at least " n " years
20 years A, D, H, I, J, Q
15 years B, E, K, L,M, R, S
10 years C, F, G, N, O, P, T, U, V
seldom as comprehensive as that and it actuarial and parametric estimates to
is evident that small treatment differences within one standard error of the actuarial
of the order of 5% will rarely be found to estimate. The skewed extrapolated actu-
be significant. arial model gives consistently lower esti-
Using a similar format to Table VII, mates for the survival fraction than
a comparison of the observed 10-year those given by the other models. The
survival fractions with those calculated low values given by the skewed extra-
from the parametric models for stage polated actuarial model for stages II and
groups I and II, and ofthe 7-year survival III are due to thefactthatthis distribution
fraction for stage group III, is given in has a very broad peak. The 7-year
Table VIII. For the lognormal, skew survival fraction was chosen as the
exponential ( = 0.5), negative exponen- criterion for stage III as almost all cancer
tial and extrapolated actuarial models, deaths among patients first seen in this
there is nearly always agreement between stage will have occurred before 10 years542 R. F. MOULD AND J. W. BOAG
have elapsed, so that the 10-year survival The format of Tables IX-XI is similar
fraction is virtually identical with the to that of Tables VII and VIII.
estimate of C. Close agreement was Tables VII and VIII give the results
observed between the extrapolated actu- calculated from the long-term follow-up
arial and negative exponential. These data and a single column of figures
2 models, and the skew exponential appears beneath the heading for each
model, gave predictions for 10-year and model. Tables IX-XI give results based
7-year survival fractions which agreed on short-term follow-up information and
fairly well with those given by the log- the date at which the predictions were
normal model, taking a fixed value of made is defined as " n years after the
S in the range 0 30-0 45. series closed " (see notation in Fig. 1).
Hence for Tables IX and X (for carcinoma
cervix stages I and II) there are 2 columns
(c) Eotimation of the long-term survival Of figures beneath the heading for each
fraction when only relatively short-term model. They correspond to predictions
follow-up data are available made at 4 years or 3 years after the series
The data already presented confirm closed (n = 4 and n = 3). In Table XI
that several of the statistical models for stage III carcinoma cervix, the pre-
examined can provide an accurate repre- dictions were made at 2 years or 1 year
sentation of the life experience of car- after the series closed (n = 2 and n = 1).
cinoma cervix patient groups when long- Figures 5 and 6 show the results for
term follow-up data are used to estimate treatment series A, B and C which are
the parameters of the model. It is quoted in Table IX, and in addition
therefore of great interest to determine results for the lognormal model with
with what accuracy the subsequent life fixed values of S ranging from 0-25 to
experience can be predicted when only 0 50 and also for the same analysis
shorter term follow-up data are used, carried out for n 2 years. Series A,
as would normally be the case in a planned B and C represent the combined data
clinical trial some 5-8 years from its for stage I of the 4 London teaching
commencement. To do this, the para- hospitals for the three 5-year treatment
meters of the statistical model to be periods 1945-49, 1950-54 and 1955-59.
tested were first estimated by the method A similar combination of data for stage II
of maximum likelihood from the incom- has been annotated W, X and Y, see
plete follow-up data which would have Table XII.
been available in our series after only a
limited follow-up period and these esti- DISCUSSION
mated parameters were used to calculate TiscUlm ION
the expected 10-, 15- or 20-year survival Type I 8tatistical models
fractions. These extrapolated survival The lognormal model.-The lognormal
fractions were then compared with the model with 3 floating parameters, M, S
actual survival fraction calculated by and C, requires for its stability a larger
the actuarial method from the long-term number of cases than are available in
follow-up data on the same group of most of our quinquennial stage groups
cases (see Fig. 1). The results for the even when long-term follow-up is avail-
several models, both type I and type II able. This was evident in the study of
(Table III), are set out in Tables IX, X " information content " in the original
and XI, for disease stages I, II and III publication (Boag, 1949) and has been
respectively. For stages I and II, the confirmed in other practical examples
10-year and 15-year survival fractions (Wood and Boag, 1950; Smithers et
are shown but for stage III the 7-year and al., 1952; Mould, 1973). However, the
10-year fractions were calculated instead. lognormal model with M and C floatingESTIMATING SUCCESS RATE IN TREATMENT OF CARCINOMA CERVIX UTERI 543
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[STAGE I [STAGE IIl
*8 6 *6
. A M W
A~~~~~~
*7 - ~ .5
.2 B _g 6 4 N 275]i =
5~~~S *A 25 3J0*3 0*4 0S 5*3 5*4 5*5
L. .
Value assumed for S Value assumed for S
using the Lognormal Model using the Lognormal Model
N=Total cases in series
Mlinimum follow-up period = *4years,x 3years,2years.
FIG. 6.-Comparison of observed and predicted 15-year survival fractions for stage I and stage II
cervix carcinoma.
TABLE XJJ.-Groupings by Stage, Hospital but with S fixed at an appropriate va.lue
and Treatment Period for Fig. 5 and 6 has been shown to give an excellent fit
with survival time distributions both in
Treatment Total Reference the presentheerienorm
Hospital period Stage cases letter t series (Table V)landnin
CHUM 1945-49 I 138 A numerous other series. To show how CHUM m 1950-54 I 179 B predictions vary with the value of S
CHUM 1955-59 I 265 C chosen, we have carried out predictive CHUM 1945-49 II 2375 calculations for the 6 values from S S25 CHUM 1950-54 II .371 X
CHUM 1955-59 II 400 Y to S =O05O in steps of O-O5. WhenESTIMATING SUCCESS RATE IN TREATMENT OF CARCINOMA CERVIX UTERI 547
long-term follow-up data are used, the the actuarial value. This is due to the
predicted 10-year survival fractions for fact that, in this series, 7 patients died
the various values of S in this range do from carcinoma cervix 12-20 years subse-
not usually differ by more than 0 03. quent to treatment and this frequency
With short-term follow-up data, however, of later recurrences is unusual.
extending over only 3 or 4 years subse- For stage II carcinoma cervix, 10-year
quent to treatment, the long-term extra- and 15-year survival fractions, there is
polated survival fractions depend more good agreement between actuarial cal-
strongly on the value of S adopted and culation and lognormal prediction for
in Tables VII-XI we have listed only S 0 30, 0 35 and 0 40, and for n = 4
the estimates based on the three central years and n 3 years. The largest
values S = 0 30, 0 35, 0 40. Figures 5 discrepancies occur when S 0 40 and
and 6 show the trends over the wider n = 3 years (Table X). Results for
range of S. stages I and II carcinoma cervix have not
For stage I carcinoma cervix, 10-year been included for the shortest follow-up
survival fraction, there is good agreement (n 2 years) since good agreement could
between actuarial calculation (" proof ", not be expected after only 2 years in
see Fig. 1) and lognormal prediction these early stages where recurrence tends
(" prediction ", see Fig. 1) for fixed values to be longer delayed.
of S equal to 0 30, 0-35 or 0 40, and for For stage III carcinoma cervix, 7-year
both n = 4 years and n = 3 years short- and 10-year survival fractions, there is
term follow-up information (Table IX). reasonable agreement between actuarial
The largest discrepancy occurs for series calculation and lognormal prediction for
F, when n = 3 years and S _ 0 40. For n = 2 years (Table XI).
this series (Table IX) no results were A summary of these conclusions is
obtained using the skew exponential shown in Table XIII. The choice of S
model since the iterative procedure did equal to 0 30 is not recommended because
not converge, while the standard errors when testing the analytical form of the
of the parameters in all the other models survival time distribution of patients
were very large indeed. Evidently this known to have died with carcinoma
series had a somewhat abnormal time cervix present, this particular value of S
distribution. in the lognormal curve did not provide
There is also a good general agreement an adequate fit to most of the data
between actuarial calculation and log- under review (see Results, (a)). The
normal prediction of the 15-year survival lognormal curve with S = 0 40 provided
fractions for stage I carcinoma cervix. a fit to more data than the S = 0 35
Discrepancies occur again for series F, curve, but the data of Tables IX-XI
and also for series B with S 0 40 andc indicate that either value is suitable for
n = 4 years (but not for n 3 years!). the purpose of predicting long-term sur-
For series A, the predicted 15-year vival fractions.
survival fractions are always higher than The skew exponential model.-Although
TABLE XIII.-Summary of Conditions for the Use of the Lognormal Model to Predict
Long-term Survival Fractions for Carcinoma Cervix
Minimum waiting period after a
Values which may be 5-year treatment series closes before
Carcinoma assumed for the lognormal use of the lognormal model No. of cases in the
cervix stage parameter S (n years) series tested*
I S=0-35-S=0-40 n=3 101-553
II S=0 35-S=0 40 n=3 68-152
III S=0-35-S==040 n=2 77-170
* See Table II.548 R. F. MOULD AND J. W. BOAG
a maximum likelihood solution was always estimates are of little practical value and
found for the skew exponential model this model cannot be regarded as suitable
for stage 1 carcinoma cervix when long- for stage I series with sample sizes
term follow-up data were used, the equa- similar to those available for this study.
tions did not always yield a solution For stage II carcinoma cervix, there
when only short-term data were available. is better agreement when n = 4 years
This failure of the iterative procedure to than when n = 3 years, and for n = 3
converge in 3 of 7 series when n - 4 years the model is satisfactory for only
and n = 3 years, indicates that this some half of the series studied (Table X).
model is unsuitable for predictive esti- For stage III carcinoma cervix, the
mates on stage I series. It is perhaps negative exponential model is unsatis-
surprising that in those cases where a factory when n 1 year, but when
solution did exist good agreement was n - 2 years the results are comparable
found between observation and prediction with those obtained using the other type I
(Table IX). models (Table XI).
For stage II carcinoma cervix, the
results using the skew exponential model Type II statistical models
were inferior to those obtained with the The extrapolated actuarial model.-The
lognormal model. This is particularly extrapolated actuarial model was intro-
noticeable for short-term follow-up when duced by Haybittle (1959) mainly for
n = 3 years. Of the 9 stage II series carcinoma breast data but has also been
in Table X, only series P showed a large used by him for 2 series of carcinoma
proportion of the cancer deaths occurring cervix patients obtained from follow-up
before the analysis time n = 4 years. information reported by Sorensen (1958)
Also, most of the remaining patients and by University College Hospital (1958).
who would eventually die with cancer However, only estimates of C were de-
present were then already showing a rived and the efficiency of the model for
recurrence. (This may reflect some dif- predicting 10-year and 15-year survival
ferences in staging.) This high propor- fractions from short-term data was not
tion of early cancer deaths has a more discussed (Haybittle, 1960).
marked influence on the skew exponential For stage I carcinoma cervix, it is
model than on the other models, since seen from Table IX that the predicted
the area under the " tail " of the skew values of the 10-year survival fractions
exponential curve is larger than that of using the type I negative exponential
the similar curves in the other models. model and the type II extrapolated
This explains the low survival fractions actuarial model are very similar. How-
predicted for series P using this model. ever, each of the model parameters a
For stage III carcinoma cervix, the and , is often subject to a standard
skew exponential model is unsatisfactory error of some 50% of its value, so these
for n - 1 year, but for n = 2 years the models are unsuitable for use with car-
results are comparable with those obtained cinoma cervix stage I series.
using the other type I statistical models For stage II carcinoma cervix series,
(Table XI). the extrapolated actuarial model does
The negative exponential model.-For not always give good agreement with
stage I carcinoma cervix, short-term actuarial estimates of long-term survival
follow-up when n = 3 years, the standard rates (Table X).
error in the negative exponential para- For stage III carcinoma cervix, the
meter ac, was greater than 0-5a in 3 of model is unsatisfactory for n = 1 year,
the 7 series (Table IX). Thus although but for n = 2 years the results are
there is generallygood agreement between comparable with those obtained using
actuarial calculation and prediction, the type I statistical models (Table XI).ESTIMATING SUCCESS RATE IN TREATMENT OF CARCINOMA CERVIX UTERI 549
The skewed extrapolated actuarial term results can be made, within cal-
model. Only one type II statistical model culable error limits.
has previously been suggested, namely, Three parametric statistical models
the extrapolated actuarial model, and this have previously been described, the log-
model postulated an exponential mortality normal (Boag, 1949), the negative expo-
curve with maximum at time zero. A nential (Berkson and Gage, 1952) and
skew curve rising to a peak within the the extrapolated actuarial (Haybittle,
first year or two might be expected to 1959). Each of these models makes a
represent the mortality curve with greater different assumption about the analytical
accuracy and the skewed extrapolated form of the distribution of survival
actuarial model was devised as a possible times of the unsuccessful cases.
improvement. The form of this curve is In the present study, the validity of
M(t) - (log C62t e-4 these several survival time distributions
has been assessed, using the x2 test, with
but the peak proved to be too broad and reference to 27 different series ofcarcinoma
generally too far from the origin to of the cervix patients, drawn from several
provide a good fit for the survival time hospitals. The patients had all been at
distribution (Results, (a)) and its use risk for at least 10 years, having been
in a predictive model is therefore some- treated during the period 1945-59 and
what artificial. For carcinoma cervix followed up until 1969-71. Two further
stages I and II the predicted values were survival time distributions were intro-
found to be inferior to those derived duced and tested-the skew exponential
from the ordinary extrapolated actuarial and the skewed extrapolated actuarial.
model, and for stage III they were similar A summary of the results of the tests
to those of the other models tests (Tables for goodness of fit is given in Table VI.
IX, X and XI). The lognormal and the skew exponential
No doubt single-parameter skew curves with C- 05 give the best fit to the
could be found, possibly from the family observed data.
given by Equation 4, which would provide Previous tests of these parametric
a better fit but since the lognormal, models have generally been limited to
with S fixed, has now been shown to checking the goodness offit ofthe survival
be of rather wide application (see log- time distribution with the proposed for-
normal model, Discussion) there are little mula, but the extrapolated actuarial
incentive to seek alternatives which are model has also been tested by comparing
likely to be analytically much less con- predicted long-term survival rates with
venient. the observed values for carcinoma of the
breast (Haybittle, 1965).
In the present study, all 5 models
CONCLUSIONS referred to above have been tested as
Parametric models seem to provide predictive models for carcinoma of the
a useful alternative to the actuarial cervix with the results shown in Fig. 1,
method ofcalculating survival percentages 5 and 6 and Tables IX, X and XI. When
even when follow-up data are sufficiently all these models are tested on stage I
extensive to allow the latter method to cases, the lognormal is consistently the
be used (Mould, 1976). They certainly most accurate in its prediction of longer
extract more information from the clinical term results; the other 4 models sometimes
data than the crude m year survival fail to give any satisfactory solution.
figures which are still the common form For stage II cases, the lognormal is still
of reporting treatment results in clinical the best model but the disparity between
journals. They offer the unique ad- this and the other models is not so
vantage that an early prediction of longer marked. For stage III cases, where the550 R. F. MOULD AND J. W. BOAG
number of long-term survivors is inevit-
ably comparatively small, there are under-
standably no great differences between
the predictions from the several models.
In summary, the lognormal model,
with S fixed at an appropriate value
(Table XIII), has been shown to be of
wider validity than any of the other
models tested and to give reliable extra-
polated estimates of long-term survival
rate for the separate stage groups in
carcinoma ofthe cervix.
We are indebted to the following
consultant radiotherapists and surgeons
for access to the data on which this
work is based and for permission to
publish it: Mr J. B. Blaikley, Dr V. M.
Dalley, Professor E. C. Easson, Dr E. W.
Emery, Professor P. Kolstad, Dr M.
Lederman, Dr R. Morrison, Dr M. D.
Snelling and Dr L. H. Walter. We
should also like to thank Miss V. S.
Waters for secretarial assistance.
REFERENCES
BERKSON, J. & GAGE, R. P. (1952) Survival Curve
for Cancer Patients following Treatment. J. Am.
stat. Soc., 47, 501.
BOAG, J. W. (1948) The Presentation and Analysis
of the Results of Radiotherapy. Br. J. Radiol.,
21, Pt I, 128, Pt II, 189.
BOAG, J. W. (1949) Maximum Likelihood Estimates
of the Proportion of Patients Cured by Cancer
Therapy. J. R. statist. Soc., (Series B), 11, 15.
CUTLER, S. J. & EDERER, F. (1958) Maximum
Utilisation of the Life Table Method in Analysing
Survival. J. chron. Dis., 8, 699.
FISHER, R. A. (1922) On the Mathematical Founda-
tions of Theoretical Statistics. Phil. Trans. R.
Soc. A, 222, 309.
GREENWOOD, M. (1926) A Report on the Natural
Duration of Cancer. Rep. Pub. Hlth med. Subj.,
bond., No. 33.
HAYBITTLE, J. L. (1959) The Estimation of the
Proportion of Patients Cured after Treatment
for Cancer of the Breast. Br. J. Radiol., 32,
725.
HAYBITTLE, J. L. (1960) The Early EstimatioiL
of the Results of Treatment for Cancer. Br.
J. Radiol., 33, 502.
HAYBITTLE, J. L. (1965) A Two-parameter Model
for the Survival Curve ofTreated Cancer Patients.
J. Am. statist. Ass., 60, 16.
LEA, D. E. (1945) The Biological Assay of Car-
cinogens. Cancer Res., 5, 633.
MERRELL, M. & SHULMAN, L. E. (1955) Deter-
mination of Prognosis in Chronic Disease Illus-
trated by Systemic Lupus Erythematosus. J.
chron. Dis. 1 12.
MOULD R. F. (1973) Statistical Models for Studying
Long Term Survival Results following Treatment
for Carcinoma of the Cervix. Ph.D. Thesis
University of London.
MOULD R. F. (1976) Calculation of Survival Rates
by the Life Table and Other Methods. Clin.
Radiol. In the press.
O.P.C.S. (1970) Report of the Advisory Committee
on Cancer Registration p. 10.
RONNIKE F. (1968) Carcinoma of the Vulva. Cure
after Operative Therapy Evaluated in Accordance
with Boag's Statistical Method. Dan. med.
Bull. 15, 296.
SMITHERS D. W. RIGBY-JONES P. GALTON,
D. A. G. & PAYNE P. M. (1952) Cancer of the
Breast. Br. J. Radiol. Suppl. 4.
SORENSEN B. (1958) Late Results of Radium
Therapy in Cervical Carcinoma. (A Clinical-
statistical Study on 798 Patients Treated at
the Radium Centre Copenhagen during the
period 1922-29.) Acta Radiol. Suppl. 169.
UNIVERSITY COLLEGE HOSPITAL (1958) Malignant
Disease at University College Hospital 1946-50.
Shrewsbury: Wilding and Son Ltd.
WOOD C. A. P. & BOAG J. W. (1950) Researches
on the Radiotherapy of Oral Cancer. MRC
Special Report Series No. 267.